Kelsey S Lau-Min1,2, Yimei Li3,4, Jennifer R Eads1, Ronac Mamtani1,2, Kelly D Getz3,5. 1. Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 2. Penn Center for Cancer Care Innovation, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania. 3. Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 4. Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. 5. Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Abstract
BACKGROUND: Timely targeted treatment initiation can be challenging because additional biomarker testing is needed for eligibility. The authors hypothesized that timely targeted treatment improves survival relative to nontimely initiation in metastatic HER2+ gastroesophageal adenocarcinoma (GEA). METHODS: The authors performed a retrospective cohort study of metastatic HER2+ GEA treated with first-line (1L) systemic therapy from January 2011 to December 2017 using a nationwide electronic health record-derived deidentified database. Timely targeted treatment-trastuzumab initiation within 14 days after starting 1L chemotherapy-was assessed as a time-varying exposure. Nontimely targeted treatment included patients who initiated trastuzumab after 14 days or who lacked documentation of receiving trastuzumab. Extended Cox regressions compared overall survival (OS) and progression-free survival (PFS) between timely and nontimely groups. RESULTS: A total of 320 patients were included; 59.1% received timely trastuzumab. Relative to nontimely initiation, timely trastuzumab was associated with significantly higher OS (2-year OS, 32.1% vs 15.3%; adjusted hazard ratio [HR], 0.67; 95% CI, 0.51-0.88) and PFS (2-year PFS, 9.2% vs 3.7%; adjusted HR, 0.71; 95% CI, 0.55-0.93). Results remained similar in sensitivity analyses 1) using alternative "timeliness" definitions up to 70 days after starting 1L chemotherapy, 2) comparing any trastuzumab, regardless of timing of initiation, to no trastuzumab, and 3) excluding patients lacking documentation of receiving trastuzumab. CONCLUSIONS: Improved survival was observed among metastatic HER2+ GEA patients treated with trastuzumab versus those who were not, regardless of timing of initiation. Although these results reassure clinicians that modest targeted treatment delays may not be detrimental to outcomes, efforts should still ensure that all metastatic HER2+ GEA patients receive trastuzumab.
BACKGROUND: Timely targeted treatment initiation can be challenging because additional biomarker testing is needed for eligibility. The authors hypothesized that timely targeted treatment improves survival relative to nontimely initiation in metastatic HER2+ gastroesophageal adenocarcinoma (GEA). METHODS: The authors performed a retrospective cohort study of metastatic HER2+ GEA treated with first-line (1L) systemic therapy from January 2011 to December 2017 using a nationwide electronic health record-derived deidentified database. Timely targeted treatment-trastuzumab initiation within 14 days after starting 1L chemotherapy-was assessed as a time-varying exposure. Nontimely targeted treatment included patients who initiated trastuzumab after 14 days or who lacked documentation of receiving trastuzumab. Extended Cox regressions compared overall survival (OS) and progression-free survival (PFS) between timely and nontimely groups. RESULTS: A total of 320 patients were included; 59.1% received timely trastuzumab. Relative to nontimely initiation, timely trastuzumab was associated with significantly higher OS (2-year OS, 32.1% vs 15.3%; adjusted hazard ratio [HR], 0.67; 95% CI, 0.51-0.88) and PFS (2-year PFS, 9.2% vs 3.7%; adjusted HR, 0.71; 95% CI, 0.55-0.93). Results remained similar in sensitivity analyses 1) using alternative "timeliness" definitions up to 70 days after starting 1L chemotherapy, 2) comparing any trastuzumab, regardless of timing of initiation, to no trastuzumab, and 3) excluding patients lacking documentation of receiving trastuzumab. CONCLUSIONS: Improved survival was observed among metastatic HER2+ GEA patients treated with trastuzumab versus those who were not, regardless of timing of initiation. Although these results reassure clinicians that modest targeted treatment delays may not be detrimental to outcomes, efforts should still ensure that all metastatic HER2+ GEA patients receive trastuzumab.
Authors: Colin T Murphy; Thomas J Galloway; Elizabeth A Handorf; Brian L Egleston; Lora S Wang; Ranee Mehra; Douglas B Flieder; John A Ridge Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: Evan M Graboyes; Anvesh R Kompelli; David M Neskey; Emily Brennan; Shaun Nguyen; Katherine R Sterba; Graham W Warren; Chanita Hughes-Halbert; Brian Nussenbaum; Terry A Day Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-02-01 Impact factor: 6.223
Authors: Kelsey S Lau-Min; Yimei Li; Jennifer R Eads; Xiaoliang Wang; Neal J Meropol; Ronac Mamtani; Kelly D Getz Journal: Cancer Date: 2021-03-17 Impact factor: 6.921
Authors: Alok A Khorana; Katherine Tullio; Paul Elson; Nathan A Pennell; Stephen R Grobmyer; Matthew F Kalady; Daniel Raymond; Jame Abraham; Eric A Klein; R Matthew Walsh; Emily E Monteleone; Wei Wei; Brian Hobbs; Brian J Bolwell Journal: PLoS One Date: 2019-03-01 Impact factor: 3.240
Authors: Eugene B Cone; Maya Marchese; Marco Paciotti; David-Dan Nguyen; Junaid Nabi; Alexander P Cole; George Molina; Rose L Molina; Christina A Minami; Lorelei A Mucci; Adam S Kibel; Quoc-Dien Trinh Journal: JAMA Netw Open Date: 2020-12-01
Authors: Melissa D Curtis; Sandra D Griffith; Melisa Tucker; Michael D Taylor; William B Capra; Gillis Carrigan; Ben Holzman; Aracelis Z Torres; Paul You; Brandon Arnieri; Amy P Abernethy Journal: Health Serv Res Date: 2018-05-14 Impact factor: 3.402